Prot #NBI-98854-ATS3019: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia

Project: Research project

Project Details

StatusActive
Effective start/end date5/14/24 → 5/14/27

Funding

  • Quintiles, Inc. (Prot #NBI-98854-ATS3019 // Prot #NBI-98854-ATS3019)
  • Neurocrine Biosciences, Inc. (Prot #NBI-98854-ATS3019 // Prot #NBI-98854-ATS3019)